Dyslipidemia and Rate of Under-Target Low-Density Lipoprotein-Cholesterol in Patients with Coronary Artery Disease in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이상학 | - |
dc.contributor.author | 송우혁 | - |
dc.contributor.author | 정명호 | - |
dc.contributor.author | 허승호 | - |
dc.contributor.author | 전동운 | - |
dc.contributor.author | 정원주 | - |
dc.contributor.author | Anselm K Gitt | - |
dc.contributor.author | Martin Horack | - |
dc.contributor.author | Ami Vyas | - |
dc.contributor.author | Dominik Lautsch | - |
dc.contributor.author | Baishali Ambegaonkar | - |
dc.contributor.author | Philippe Brudi | - |
dc.contributor.author | 장양수 | - |
dc.date.accessioned | 2021-12-14T20:41:25Z | - |
dc.date.available | 2021-12-14T20:41:25Z | - |
dc.date.created | 2021-08-31 | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 2287-2892 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/131561 | - |
dc.description.abstract | Objective: The aim of this study was to evaluate under target rates of low-density lipoproteincholesterol (LDL-C) in Korean patients with stable coronary artery disease (CAD) or an acute coronary syndrome (ACS) in real world practice. Methods: Dyslipidemia International Study II was an international observational study of patients with stable CAD or an ACS. Lipid profiles and use of lipid-lowering therapy (LLT) were documented at enrollment, and for the ACS cohort, 4 months follow-up was recommended. Rates of under target LDL-C as per European guidelines, were evaluated, and multivariate regression was performed to identify predictive factors of patients presenting under the target. Results: A total of 808 patients were enrolled in Korea, 500 with stable CAD and 308 with ACS. Of these, 90.6% and 52.6% were being treated with LLT, respectively. In the stable CAD group, 40.0% were under target LDL-C, while in ACS group, the rate was 23.7%. A higher statin dose was independently associated with under target LDL-C in both groups (OR, 1.03; p=0.046 [stable CAD] and OR, 1.05; p=0.01 [ACS]). The mean statin dosage (atorvastatin equivalent) was 17 mg/day. In the 79 ACS patients who underwent the follow-up examination, the LDL-C under target rate rose to 59.5%. Conclusion: Only a minority of patients with stable CAD or ACS were under their target LDL-C level at enrollment. The statin dose was not sufficient in the majority of patients. These results indicate a considerable LLT gap in Korean patients with established CAD. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | 한국지질동맥경화학회 | - |
dc.title | Dyslipidemia and Rate of Under-Target Low-Density Lipoprotein-Cholesterol in Patients with Coronary Artery Disease in Korea | - |
dc.title.alternative | Dyslipidemia and Rate of Under-Target Low-Density Lipoprotein-Cholesterol in Patients with Coronary Artery Disease in Korea | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 송우혁 | - |
dc.identifier.doi | 10.12997/jla.2019.8.2.242 | - |
dc.identifier.bibliographicCitation | 지질·동맥경화학회지, v.8, no.2, pp.242 - 251 | - |
dc.relation.isPartOf | 지질·동맥경화학회지 | - |
dc.citation.title | 지질·동맥경화학회지 | - |
dc.citation.volume | 8 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 242 | - |
dc.citation.endPage | 251 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART002503840 | - |
dc.description.journalClass | 2 | - |
dc.description.journalRegisteredClass | kci | - |
dc.description.journalRegisteredClass | other | - |
dc.subject.keywordAuthor | Cholesterol | - |
dc.subject.keywordAuthor | Hydroxymethylglutaryl-CoA reductase inhibitors | - |
dc.subject.keywordAuthor | Acute coronary syndrome | - |
dc.subject.keywordAuthor | Coronary artery disease | - |
dc.subject.keywordAuthor | Dyslipidemias | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.